Related Experiment Videos
New hypoglycaemic agents selected by molecular topology
C Calabuig1, G M Antón-Fos, J Gálvez
1Unidad de Investigación de Diseño de Fármacos y Conectividad Molecular, Dpto. de Química Física, Facultad de Farmacia, Universitat de Valencia, Valencia, Spain.
International Journal of Pharmaceutics
|May 26, 2004
Summary
Computer-aided design identified new compounds with hypoglycaemic activity. These novel agents show potential for diabetes management, with some comparable to tolbutamide but with improved safety profiles.
Area of Science:
- Medicinal Chemistry
- Computational Chemistry
- Pharmacology
Background:
- Diabetes mellitus remains a significant global health challenge, necessitating the development of novel therapeutic agents.
- Existing hypoglycaemic drugs can have limitations, driving the search for compounds with improved efficacy and safety profiles.
Purpose of the Study:
- To design and identify novel compounds exhibiting significant hypoglycaemic activity using computational methods.
- To predict and validate the potential of new chemical entities for managing blood glucose levels.
Main Methods:
- Quantitative Structure-Activity Relationship (QSAR) and molecular connectivity analyses were employed to model hypoglycaemic activity.
- Linear discriminant analysis was utilized to develop a predictive model based on topological indices of 89 compounds.
- A large chemical database was screened using the developed model to identify potential hypoglycaemic candidates.
Main Results:
- The QSAR model successfully predicted hypoglycaemic activity, leading to the selection of 14 potential new hypoglycaemic compounds.
- Five compounds were experimentally tested, with l-arabitol, Acid blue 161, 1,4-butanediol diglycidil ether, and Acid red 151 demonstrating significant hypoglycaemic effects.
- Acid blue 161 exhibited a glycaemic profile similar to tolbutamide but without severe hypoglycaemia, while other agents showed profiles near normality.
Conclusions:
- Computer-aided drug design effectively identified promising novel hypoglycaemic agents.
- Selected compounds, particularly Acid blue 161, represent potential therapeutic options for diabetes with a favorable safety profile compared to existing treatments.